Fulcrum Therapeutics, Inc. (FULC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 5.11 |
| Open | 5.13 |
| Bid | 4.77 x 900 |
| Ask | 5.15 x 800 |
| Day's Range | 4.96 - 5.24 |
| 52 Week Range | 3.21 - 33.10 |
| Volume | |
| Avg. Volume | 917,679 |
| Market Cap | 209.96M |
| Beta (5Y Monthly) | 2.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.38 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.38 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for FULC
Related Research
- Fulcrum Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 06/30/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast yearArgus Research
- GlobeNewswire
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the Company granted nonstatutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan. Fulcrum granted stock options to purchase an aggregate of 112,800 shares of the Company’s common stock to eight new emplo
- Simply Wall St.
Here's Why We're Watching Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- GlobeNewswire
Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell Disease Based on Initial Data from the Ongoing Phase 1b Trial
- Achieved up to 6.3% hemoglobin F (HbF) induction in initial subjects in first cohort; HbF was increasing at last measured timepoint - Supports proof-of-concept that FTX-6058 is a novel oral HbF inducer - FTX-6058 was generally well tolerated; no serious treatment emergent adverse events (TEAEs) reported - Data to be presented as a poster at European Hematology Association (EHA) Hybrid Congress; highlights to be presented at the Foundation for Sickle Cell Disease Research Symposium (FSCDR) on J
